These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 25480129)

  • 21. [Can the determination of IgG antibodies to the pertussis toxin help the diagnosis of the disease?].
    Holcíková A; Stroblová H; Jirsenská Z
    Klin Mikrobiol Infekc Lek; 2006 Oct; 12(5):184-8. PubMed ID: 17080352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Local and systemic immune responses to pertussis infection and cellular and acellular vaccines.
    Ashworth LA; Day A; Lambert HP; Lingham S; Lissauer T; Miller E; Robinson A; Rutter DA; Thomas MG
    Ann Sclavo Collana Monogr; 1986; 3(1-2):199-211. PubMed ID: 2892507
    [No Abstract]   [Full Text] [Related]  

  • 24. Construction of an unmarked recombinant BCG expressing a pertussis antigen by auxotrophic complementation: protection against Bordetella pertussis challenge in neonates.
    Nascimento IP; Dias WO; Quintilio W; Hsu T; Jacobs WR; Leite LC
    Vaccine; 2009 Dec; 27(52):7346-51. PubMed ID: 19782111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serologic response and antibody-titer decay in adults with pertussis.
    Heininger U; Cherry JD; Stehr K
    Clin Infect Dis; 2004 Feb; 38(4):591-4. PubMed ID: 14765356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin.
    Mooi FR; Van Der Maas NA; De Melker HE
    Epidemiol Infect; 2014 Apr; 142(4):685-94. PubMed ID: 23406868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resurgence of pertussis calls for re-evaluation of pertussis animal models.
    van der Ark AA; Hozbor DF; Boog CJ; Metz B; van den Dobbelsteen GP; van Els CA
    Expert Rev Vaccines; 2012 Sep; 11(9):1121-37. PubMed ID: 23151168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EUVAC.NET collaborative study: evaluation and standardisation of serology for diagnosis of pertussis.
    Xing D; Markey K; Newland P; Rigsby P; Hockley J; He Q
    J Immunol Methods; 2011 Sep; 372(1-2):137-45. PubMed ID: 21782823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunologic findings in oral pertussis vaccination].
    Kurz R; Mayr J; Höfler KH; Falk W; Rosanelli K
    Padiatr Padol; 1986; 21(1):53-9. PubMed ID: 2870453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between pertussis symptomatology, incidence and serology in adolescents.
    Cagney M; McIntyre PB; Heron L; Giammanco A; MacIntyre CR
    Vaccine; 2008 Oct; 26(44):5547-53. PubMed ID: 18723066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeling rates of infection with transient maternal antibodies and waning active immunity: application to Bordetella pertussis in Sweden.
    Feng Z; Glasser JW; Hill AN; Franko MA; Carlsson RM; Hallander H; Tüll P; Olin P
    J Theor Biol; 2014 Sep; 356():123-32. PubMed ID: 24768867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The host defense peptide beta-defensin 1 confers protection against Bordetella pertussis in newborn piglets.
    Elahi S; Buchanan RM; Attah-Poku S; Townsend HG; Babiuk LA; Gerdts V
    Infect Immun; 2006 Apr; 74(4):2338-52. PubMed ID: 16552064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen.
    Mooi FR
    Infect Genet Evol; 2010 Jan; 10(1):36-49. PubMed ID: 19879977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of safer pertussis DNA vaccine expressing non-toxic C180 polypeptide of pertussis toxin S1 subunit.
    Kamachi K; Arakawa Y
    Vaccine; 2007 Jan; 25(6):1000-6. PubMed ID: 17050047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective effects of vaccines against Bordetella parapertussis in a mouse intranasal challenge model.
    Komatsu E; Yamaguchi F; Eguchi M; Watanabe M
    Vaccine; 2010 Jun; 28(27):4362-8. PubMed ID: 20438876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the duration of pertussis immunity using epidemiological signatures.
    Wearing HJ; Rohani P
    PLoS Pathog; 2009 Oct; 5(10):e1000647. PubMed ID: 19876392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.
    Hallander HO; Ljungman M; Jahnmatz M; Storsaeter J; Nilsson L; Gustafsson L
    APMIS; 2009 Sep; 117(9):660-71. PubMed ID: 19703126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reciprocal protective immunity against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection.
    Watanabe M; Nagai M
    Infect Immun; 2001 Nov; 69(11):6981-6. PubMed ID: 11598073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamics of transplacental transmission of pertussis antibodies in premature and full-term infants.
    Nomura M; Kuno-Sakai H; Kimura M; Ichikawa I
    Tokai J Exp Clin Med; 2003 Apr; 28(1):21-6. PubMed ID: 12880300
    [No Abstract]   [Full Text] [Related]  

  • 40. Waning immunity and sub-clinical infection in an epidemic model: implications for pertussis in The Netherlands.
    van Boven M; de Melker HE; Schellekens JF; Kretzschmar M
    Math Biosci; 2000 Apr; 164(2):161-82. PubMed ID: 10748285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.